Ultragenyx Pharmaceutical (RARE) Change in Acquisitions & Divestments (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Change in Acquisitions & Divestments data on file, last reported at $88.0 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $88.0 million, down 35.77% year-over-year; the trailing twelve-month figure through Mar 2026 was -$49.0 million (down 537.27% YoY), and the FY2024 annual result was $3.0 million, down 99.57% from the prior year.
• Change in Acquisitions & Divestments rose to $88.0 million in Q1 2026 per RARE's latest filing, from -$143000.0 in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $567.6 million in Q3 2023 and troughed at -$323.7 million in Q4 2022.
• A 5-year average of $54.5 million and a median of $98.2 million in 2022 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2022 and 2023: Change in Acquisitions & Divestments plunged 3479.11% in 2022, then jumped 413.1% in 2023.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at -$323.7 million in 2022, then soared by 135.15% to $113.8 million in 2023, then sank by 100.13% to -$148000.0 in 2024, then climbed by 3.38% to -$143000.0 in 2025, then soared by 61638.46% to $88.0 million in 2026.
• Business Quant data shows RARE's Change in Acquisitions & Divestments at $88.0 million in Q1 2026, -$143000.0 in Q4 2025, and -$136.9 million in Q2 2025.